Infinity Pharmaceuticals Inc. (NASDAQ:INFI) was the recipient of a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 69,300 shares, a drop of 20.3% from the December 31st total of 87,000 shares. Based on an average daily volume of 140,400 shares, the short-interest ratio is currently 0.5 days. Currently, 0.1% of the company’s shares are short sold.
Shares of INFI stock traded down $0.05 on Monday, reaching $1.40. 8,585 shares of the stock were exchanged, compared to its average volume of 234,793. The company has a current ratio of 6.22, a quick ratio of 6.22 and a debt-to-equity ratio of 0.11. The business’s 50 day moving average price is $1.15 and its 200 day moving average price is $1.21. The company has a market capitalization of $79.65 million, a price-to-earnings ratio of -1.84 and a beta of 1.82. Infinity Pharmaceuticals has a twelve month low of $0.82 and a twelve month high of $1.95.
Infinity Pharmaceuticals (NASDAQ:INFI) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). Infinity Pharmaceuticals had a negative return on equity of 125.37% and a negative net margin of 1,519.91%. The firm had revenue of $0.34 million for the quarter, compared to analyst estimates of $0.85 million. Equities research analysts forecast that Infinity Pharmaceuticals will post -0.83 earnings per share for the current year.
Several equities analysts have commented on INFI shares. B. Riley started coverage on shares of Infinity Pharmaceuticals in a research note on Monday, November 18th. They issued a “buy” rating and a $3.50 price target for the company. ValuEngine downgraded shares of Infinity Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $2.83.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Further Reading: Asset Allocation, Balancing Your Investments
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.